Ozempic and Mounjaro May Benefit Brain Health, New Research Suggests

Blockbuster weight-loss drugs Ozempic (semaglutide) and Mounjaro (tirzepatide) may offer benefits beyond weight loss. A new review published November 17, 2026, in Science (DOI: 10.1126/science.aek9987) highlights growing evidence that GLP-1 receptor agonists could influence cognitive and neurological health.

Analyses of large health-record databases have found an association between GLP-1 treatment and a lower risk of dementia among people with type 2 diabetes. Researchers suggest these potential cognitive effects may stem from improved metabolic health, direct anti-inflammatory actions in the brain, or a combination of both. Scientists from the University of Gothenburg and the University of Copenhagen are among those studying how these drugs affect brain processes involved in memory and learning.

Major clinical trials focused on Alzheimer’s disease—including Novo Nordisk’s EVOKE and EVOKE+ studies—have not yet demonstrated that these drugs directly slow cognitive decline. Researchers say the observational evidence is promising, but further investigation is needed. Large-scale human clinical trials will be essential before GLP-1 drugs can be recommended to help preserve brain health.

Source: ScienceDaily — November 17, 2026

Move to the category:

Leave a Reply

Your email address will not be published. Required fields are marked *